Compare ASE Technology Holding Co Ltd (ASX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs 10X Genomics Inc — how do they compare? ASE Technology Holding Co Ltd trades at $40.55 (market cap $87.94B), while 10X Genomics Inc trades at $45.28 (market cap $5.81B). The key difference: ASE Technology Holding Co Ltd is far larger — about 15.1× 10X Genomics Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.03% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| ASX | TXG | |
|---|---|---|
Market Cap | $87.94B | $5.81B |
Sector | Technology | Health |
52-Week High | $45.12 | $45.80 |
52-Week Low | $9.50 | $11.34 |
Enterprise Value | $92.38B | $5.36B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $40.56, down 4.92% over 24 hours, with a neutral technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and robust cash flow growth. Revenue reached $645.39B in 2025 with net income of $40.02B, while analyst sentiment remains positive with 80% buy ratings. Recent news highlights AI-driven packaging demand and LEAP business growth exceeding $3.5B in 2026 revenue outlook.
The stock presents growth potential from AI infrastructure demand and margin expansion, though elevated P/E ratio of 63.65 suggests premium valuation. Key risks include semiconductor cycle volatility and execution challenges in scaling advanced packaging capacity. Institutional ownership trends and positive earnings revisions support the bullish case, but investors should monitor competitive pressures in the semiconductor packaging sector.
TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.
The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
